5 April 2021 - The evidence suggests CAR-Ts ide-cel and cilta-cel both have the potential to help patients live substantially longer with manageable side effects, although ide-cel’s recently announced price would still require at least a 37% discount to reach ICER’s recommended health-benefit price benchmark.

The Institute for Clinical and Economic Review today released an Evidence Report assessing the comparative clinical effectiveness and value of three new treatments targeting the B-cell maturation antigen for heavily pre-treated patients with triple class refractory multiple myeloma who have cycled through numerous previous lines of therapy.

Read ICER Announcement